Literature DB >> 23139615

Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.

Hui-Min Xu1, Yan Chen, Jie Xu, Quan Zhou.   

Abstract

AIM: To identify the proportion, causes and the nature of drug-induced liver injury (DILI) in patients with notably elevated alanine aminotransferase (ALT).
METHODS: All the inpatients with ALT levels above 10 times upper limit of normal range (ULN) were retrospectively identified from a computerized clinical laboratory database at our hospital covering a 12-mo period. Relevant clinical information was obtained from medical records. Alternative causes of ALT elevations were examined for each patient, including biliary abnormality, viral hepatitis, hemodynamic injury, malignancy, DILI or undetermined and other causes. All suspected DILI cases were causality assessed using the Council for International Organizations of Medical Sciences scale, and only the cases classified as highly probable, probable, or possible were diagnosed as DILI. Comments related to the diagnosis of DILI in the medical record and in the discharge letter for each case were also examined to evaluate DILI detection by the treating doctors.
RESULTS: A total of 129 cases with ALT > 10 ULN were identified. Hemodynamic injury (n = 46, 35.7%), DILI (n = 25, 19.4%) and malignancy (n = 21, 16.3%) were the top three causes of liver injury. Peak ALT values were lower in DILI patients than in patients with hemodynamic injury (14.5 ± 5.6 ULN vs 32.5 ± 30.7 ULN, P = 0.001). Among DILI patients, one (4%) case was classified as definite, 19 (76%) cases were classified as probable and 5 (20%) as possible according to the CIOMS scale. A hepatocellular pattern was observed in 23 (92%) cases and mixed in 2 (8%). The extent of severity of liver injury was mild in 21 (84%) patients and moderate in 4 (16%). Before discharge, 10 (40%) patients were recovered and the other 15 (60%) were improved. The improved patients tended to have a higher peak ALT (808 ± 348 U/L vs 623 ± 118 U/L, P = 0.016) and shorter treatment duration before discharge (8 ± 6 d vs 28 ± 12 d, P = 0.008) compared with the recovered patients. Twenty-two drugs and 6 herbs were found associated with DILI. Antibacterials were the most common agents causing DILI in 8 (32%) cases, followed by glucocorticoids in 6 (24%) cases. Twenty-four (96%) cases received treatment of DILI with at least one adjunctive drug. Agents for treatment of DILI included anti-inflammatory drugs (e.g., glycyrrhizinate), antioxidants (e.g., glutathione, ademetionine 1,4-butanedisulfonate and tiopronin), polyene phosphatidyl choline and herbal extracts (e.g., protoporphyrin disodium and silymarin). Diagnosis of DILI was not mentioned in the discharge letter in 60% of the cases. Relative to prevalent cases and cases from wards of internal medicine, incident cases and cases from surgical wards had a higher risk of missed diagnosis in discharge letter [odds ratio (OR) 32.7, 95%CI (2.8-374.1), and OR 58.5, 95%CI (4.6-746.6), respectively].
CONCLUSION: DILI is mostly caused by use of antibacterials and glucocorticoids, and constitutes about one fifth of hospitalized patients with ALT > 10 ULN. DILI is underdiagnosed frequently.

Entities:  

Keywords:  Abnormal liver enzyme; Adjunctive drugs; Alanine aminotransferase; Drug-induced liver injury; Underdiagnosis

Mesh:

Substances:

Year:  2012        PMID: 23139615      PMCID: PMC3491606          DOI: 10.3748/wjg.v18.i41.5972

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

Review 1.  Liver enzyme alteration: a guide for clinicians.

Authors:  Edoardo G Giannini; Roberto Testa; Vincenzo Savarino
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

2.  Presentation of drug-induced liver injury in Singapore.

Authors:  C T Wai
Journal:  Singapore Med J       Date:  2006-02       Impact factor: 1.858

3.  The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected].

Authors:  Mark V Galan; Jeffrey A Potts; Ann L Silverman; Stuart C Gordon
Journal:  J Clin Gastroenterol       Date:  2005-01       Impact factor: 3.062

4.  Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.

Authors:  Robert J Fontana; Leonard B Seeff; Raúl J Andrade; Einar Björnsson; Christopher P Day; Jose Serrano; Jay H Hoofnagle
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

5.  Methylprednisolone-induced toxic hepatitis.

Authors:  Firdevs Topal; Ersan Ozaslan; Sabiye Akbulut; Metin Küçükazman; Osman Yüksel; Emin Altiparmak
Journal:  Ann Pharmacother       Date:  2006-08-22       Impact factor: 3.154

Review 6.  Acute hepatic failure in India: a perspective from the East.

Authors:  S K Acharya; S K Panda; A Saxena; S D Gupta
Journal:  J Gastroenterol Hepatol       Date:  2000-05       Impact factor: 4.029

7.  Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals.

Authors:  H Bagheri; F Michel; M Lapeyre-Mestre; E Lagier; J P Cambus; P Valdiguié; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

8.  Polyunsaturated phosphatidylcholine lowers collagen deposition in a rat model of corrosive esophageal burn.

Authors:  S Demirbilek; G Aydin; S Yücesan; H Vural; M Bitiren
Journal:  Eur J Pediatr Surg       Date:  2002-02       Impact factor: 2.191

9.  Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.

Authors:  M García-Cortés; M I Lucena; K Pachkoria; Y Borraz; R Hidalgo; R J Andrade
Journal:  Aliment Pharmacol Ther       Date:  2008-02-18       Impact factor: 8.171

10.  A protective effect of glutathione-dextran macromolecular conjugates on acetaminophen-induced hepatotoxicity dependent on molecular size.

Authors:  Y Kaneo; K Ogawa; T Tanaka; Y Fujihara; S Iguchi
Journal:  Biol Pharm Bull       Date:  1994-10       Impact factor: 2.233

View more
  8 in total

1.  Irreversible electroporation of malignant liver tumors: Effect on laboratory values.

Authors:  Mohammed Alnaggar; Ammar M Qaid; Jibing Chen; Lizhi Niu; Kecheng Xu
Journal:  Oncol Lett       Date:  2018-07-02       Impact factor: 2.967

Review 2.  MicroRNAs in Drug-induced Liver Injury.

Authors:  Li-Min Li; Dong Wang; Ke Zen
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

3.  Is aspartate aminotransferase-to-platelet ratio index a biomarker in the evaluation of advanced fibrosis in non-alcoholic fatty liver disease?

Authors:  Mehmet Agilli; Fevzi Nuri Aydin; Tuncer Cayci; Yasemin Gulcan Kurt
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-11

4.  Clinical Features of Drug-induced Liver Injury According to Etiology.

Authors:  Byoung Moo Lee; Woong Cheul Lee; Jae Young Jang; Pyoung Ahn; Jin Nyoung Kim; Soung Won Jeong; Eui Ju Park; Sae Hwan Lee; Sang Gyune Kim; Sang-Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim
Journal:  J Korean Med Sci       Date:  2015-11-30       Impact factor: 2.153

5.  Enzymatic characterization of D-lactate dehydrogenase and application in alanine aminotransferase activity assay kit.

Authors:  Yi Sun; Guosheng Gao; Ting Cai
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Cholestatic hepatitis with small duct injury associated with celecoxib.

Authors:  Suresh Kumar Nayudu; Shanti Badipatla; Masooma Niazi; Bhavna Balar
Journal:  Case Rep Med       Date:  2013-06-05

7.  Correlations between mitochondrial DNA haplogroup D5 and chronic hepatitis B virus infection in Yunnan, China.

Authors:  Xiao Li; Tai-Cheng Zhou; Chang-Hui Wu; Li-Lin Tao; Rui Bi; Li-Jun Chen; De-Yao Deng; Chang Liu; Newton O Otecko; Yang Tang; Xin Lai; Liang Zhang; Jia Wei
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

8.  Epidemiology and outcomes of marked elevations of alanine aminotransferase >1000 IU/L in an Australian cohort.

Authors:  Danny Con; Andrew Buckle; Amanda J Nicoll; John S Lubel
Journal:  JGH Open       Date:  2019-07-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.